NASDAQ:AUTL
Autolus Therapeutics plc Stock News
$4.19
+0.0800 (+1.95%)
At Close: May 03, 2024
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
07:00am, Thursday, 29'th Feb 2024
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
03:31am, Monday, 12'th Feb 2024
Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't sugges
Autolus Upgrades Leadership And Faces CAR-T Approval
09:52am, Tuesday, 06'th Feb 2024
Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several
The Jobs Report Blows Away Forecasts
09:26pm, Friday, 02'nd Feb 2024
January's payrolls report shows 353,000 jobs
Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast
04:12am, Monday, 18'th Dec 2023
Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL
Autolus Therapeutics announces participation in upcoming conferences
07:00am, Monday, 06'th Nov 2023
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces i
Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript
10:05pm, Friday, 03'rd Nov 2023
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
08:07am, Wednesday, 11'th Oct 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
07:00am, Wednesday, 11'th Oct 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Call Transcript
07:59am, Sunday, 06'th Aug 2023
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Ju
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
07:00am, Tuesday, 18'th Jul 2023
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket
07:34pm, Friday, 30'th Jun 2023
Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative to commercial rivals. Strong cash position should see the company through to obe-cel launch.
3 Top Penny Stock Picks You Haven't Heard Of
09:39am, Wednesday, 14'th Jun 2023
Unless you regularly invest in or research penny stocks it's likely you aren't familiar with most companies in the space. These penny stock picks aren't household names because by and large they aren
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
07:00am, Thursday, 20'th Apr 2023
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript
02:04pm, Tuesday, 07'th Mar 2023
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Offic